Biohaven Ltd. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BHVN New York 2834 www.biohaven.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biohaven Ltd.

Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - Dec 6th, 2024 12:30 pm
Scholar Rock Stock Jumps As Rival Biohaven's Muscle-Wasting Drug Flunks Pivotal Study - Nov 25th, 2024 4:51 pm
Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - Nov 25th, 2024 12:30 pm
Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - Nov 12th, 2024 9:05 pm
Scholar Rock Jumps 362% On Final-Phase Win In Spinal Muscular Atrophy - Oct 7th, 2024 8:13 pm
Bullish Biohaven Insiders Loaded Up On US$41.7m Of Stock - Oct 3rd, 2024 12:22 pm
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Oct 2nd, 2024 8:05 pm
Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - Oct 1st, 2024 10:00 am
Biohaven Announces Proposed Public Offering of Common Shares - Sep 30th, 2024 8:05 pm
Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine - Sep 30th, 2024 11:30 am
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More - Sep 26th, 2024 4:06 pm
BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal - Sep 24th, 2024 2:53 pm
Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) - Sep 23rd, 2024 11:30 am
Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia - Sep 20th, 2024 11:09 pm
Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Aug 9th, 2024 12:21 am
Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments - Aug 8th, 2024 8:05 pm
Biohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day - May 29th, 2024 11:30 am
Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors - May 29th, 2024 11:15 am
Director Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN) - May 15th, 2024 3:00 pm
Down -24.55% in 4 Weeks, Here's Why Biohaven Ltd. (BHVN) Looks Ripe for a Turnaround - May 14th, 2024 1:35 pm